C4 complement blood test: levels, ranges, and interpretation

Key Takeaways

A c4 complement blood test measures the level of complement component 4 (C4) in the blood, a protein central to the classical complement pathway

Low C4 is a hallmark of active lupus (SLE), hereditary angioedema (HAE), and glomerulonephritis; high C4 can reflect acute-phase inflammation

The adult reference range is approximately 16-47 mg/dL, but always interpret results against your specific laboratory’s reference interval

Pabau’s lab management software helps clinics track repeat complement panels, flag abnormal results, and document clinical decisions in one place

What the c4 complement blood test measures and why it matters

Most patients who receive an abnormal complement result have no idea what the test was even looking for. The c4 complement blood test measures the serum concentration of complement component 4, a protein that sits at the heart of the immune system’s classical activation pathway. Clinicians order it when they suspect an autoimmune condition, need to monitor disease activity, or want to screen for a hereditary condition called angioedema.

C4 is not an inflammatory marker like CRP or ESR. It is a structural component of the complement cascade, consumed during immune activation rather than simply elevated by it. That distinction shapes how clinicians interpret results and why a single low reading can carry significant diagnostic weight.

This guide covers what C4 does in the immune system, what normal and abnormal c4 complement levels mean, how the test is performed, and what clinicians need to know when ordering it as part of a broader diagnostic workup.

How the complement system works

The complement system is a cascade of around 50 proteins that amplifies the immune response, destroys pathogens, and clears immune complexes and apoptotic cells. It activates through three pathways: classical, lectin, and alternative. C4 is exclusive to the classical pathway.

In the classical pathway, antibody-antigen complexes bind C1, which cleaves C4 into C4a and C4b. C4b deposits on the pathogen surface, initiating a chain reaction that eventually forms the membrane attack complex (MAC) and lyses the invading cell. Because C4 is consumed during this process, active immune complex disease depletes serum C4 levels.

Understanding this mechanism is essential for integrative medicine practice management and for interpreting why C4 falls in some diseases but rises in others. Clinics running autoimmune panels benefit from tracking these results longitudinally in a single patient record.

The three complement pathways at a glance

Why a doctor would order the c4 complement blood test

Clinicians reach for the c4 complement blood test in two broad scenarios: when diagnosing a condition and when monitoring a known disease for activity or treatment response. The test rarely stands alone. It is almost always ordered alongside C3, total complement (CH50), an ANA panel, or anti-dsDNA antibodies depending on clinical suspicion.

The most common indications include:

• Systemic lupus erythematosus (SLE): C4 drops during active disease flares as immune complexes consume complement. Monitoring C4 alongside C3 gives clinicians an early indicator of flare activity, often before symptoms escalate.
• Hereditary angioedema (HAE): C4 is almost always low or undetectable between episodes in HAE types I and II, making it a reliable screening marker even when the patient is not in active attack.
• Glomerulonephritis: Immune-complex-mediated kidney inflammation consumes complement, producing low C3 and C4 together.
• Rheumatoid arthritis and other autoimmune conditions: C4 is part of the broader autoimmune workup for any condition involving immune complex deposition.
• Unexplained recurrent angioedema: When patients present with episodes of non-allergic swelling without urticaria, low C4 between attacks strongly suggests HAE even when C1-inhibitor is not yet tested.

Clinics working with functional medicine and rheumatology patients benefit from functional medicine software that tracks serial complement panels across visits and surfaces trends in the clinical timeline.

How the c4 complement blood test is performed

The test requires a standard venous blood draw. No fasting is necessary, according to Mayo Clinic Laboratories and UCSF Health specimen requirements. The sample is processed as serum (clotted blood, centrifuged) or, for some assay methods, EDTA plasma.

One pre-analytical pitfall is complement consumption ex vivo: if a serum sample sits at room temperature for several hours before being processed, complement proteins including C4 can degrade, producing falsely low results. Correct handling (prompt centrifugation and storage at -70°C if testing is delayed) is essential for accurate measurement. Clinics using lab management software can record collection times and flag samples with handling delays for clinician review.

Haemolysed samples are also a source of error. Red cell contents can interfere with nephelometry-based assays, the most common measurement method for complement proteins. Any visibly haemolysed sample should be recollected.

C4 complement normal range: what the reference values mean

Reference ranges differ slightly between laboratories and assay methods. The widely cited adult range from Mayo Clinic Laboratories is approximately 16-47 mg/dL for adults. Always use the reference interval provided on your patient’s actual laboratory report, not a generic figure from a textbook or website.

For structured guidance on interpreting biomarkers without overpromising results to patients, Pabau’s clinical resource library covers the communication principles that apply to complement results as much as any other lab value.

Interpreting c4 complement levels: low, high, and in context

A single C4 value means very little without clinical context. The critical question is whether the level is appropriate for what is happening in the patient’s immune system at that moment.

Low C4 complement levels: causes and associated conditions

Low c4 complement levels signal consumption or deficiency. The most important causes include:

• Active SLE: During a lupus flare, immune complexes activate the classical pathway continuously, depleting both C3 and C4. A falling C4 often precedes clinical symptoms of a flare, making it a useful early warning signal in monitored patients.
• Hereditary angioedema (HAE): C4 is consumed when C1-inhibitor is deficient or dysfunctional (HAE types I and II). Levels are persistently low between attacks, not just during episodes. This is the key distinguishing feature from allergic angioedema, where C4 is normal between attacks.
• Glomerulonephritis: Immune complex deposition in the glomeruli activates complement locally and systemically, lowering C4 and C3 together.
• Cryoglobulinaemia: Circulating cryoglobulins activate the classical pathway, producing characteristically low C4 with a relatively preserved C3.
• C4 genetic deficiency: Homozygous C4A or C4B null alleles produce constitutively low C4 without active immune disease. This is discussed further in the clinician section below.
• Sepsis with immune complex activation: Severe infections can transiently consume complement proteins.

High C4 complement levels: causes and associated conditions

Elevated C4 is less diagnostically specific than low C4. C4 behaves as a minor acute-phase reactant, meaning levels can rise modestly during systemic inflammation. This should be interpreted cautiously and phrased carefully to patients.

Conditions associated with high c4 complement levels include:

• Active infections and systemic inflammatory states
• Certain malignancies (haematological and solid tumour)
• Pregnancy (mild physiological rise)
• Thyroiditis and other endocrine autoimmune conditions

In most cases, an isolated elevated C4 without symptoms of immune complex disease is not clinically actionable on its own. Trend monitoring alongside C3, CRP, and clinical assessment is more informative than a single elevated result.

C4 vs C3: understanding the full complement panel

C3 and C4 are almost always ordered together. They are the two most clinically accessible complement proteins and their combined pattern is more informative than either value alone. For deeper context on functional lab panel interpretation, the same principles of pattern-over-single-value apply across immunology and functional medicine testing.

CH50 (total haemolytic complement) adds another layer. A near-zero CH50 with low C4 and C3 suggests a primary complement deficiency rather than consumption. Refer to an immunologist if this pattern appears.

Track complement panels and autoimmune workups across patient visits

Pabau gives clinics a single timeline for serial lab results, clinical notes, and treatment decisions. See how it helps rheumatology and functional medicine practices stay on top of complex patient histories.

Book a demo

C4 complement testing in practice: what clinicians should know

This section addresses the practical pitfalls and nuances that competitors rarely cover. It is aimed at clinicians ordering or interpreting the test rather than patients receiving results.

Monitoring frequency in SLE and HAE

In active or recently diagnosed SLE, the American College of Rheumatology recommends monitoring complement levels at regular intervals as part of disease activity assessment. A practical approach for stable SLE is C3, C4, and anti-dsDNA every 3-6 months. During a suspected flare, immediate retesting is appropriate rather than waiting for a scheduled review.

For HAE, C4 between attacks is the most sensitive screening test available. According to the American Academy of Allergy, Asthma and Immunology (AAAAI), persistently low C4 between episodes should prompt C1-inhibitor antigen and functional testing to confirm HAE type I or II. C4 alone is not sufficient for a diagnosis.

Good safer clinical documentation of the timing and context of complement results is critical for both conditions. Noting whether a result was taken during a symptomatic episode or during remission changes its interpretation entirely.

C4A and C4B null alleles: a genetic confounder

C4 is encoded by two genes, C4A and C4B, located within the MHC class III region. Copy number varies between individuals: some people carry extra copies, others carry null alleles producing no C4A or C4B protein. Homozygous C4A null alleles occur in approximately 1-3% of the general population and are associated with persistently low serum C4 without any active immune complex disease.

This is a clinically important pitfall. A patient with a chronic low-normal C4 due to null alleles can appear to have SLE-associated complement depletion when they do not. Serial testing showing stable low C4 without dynamic changes (and without a rising anti-dsDNA) points toward genetic null alleles rather than ongoing consumption. Specialist immunogenetic testing can confirm this when the clinical picture is ambiguous.

Factors that can affect c4 complement levels

Several variables beyond the underlying disease affect c4 complement levels. Clinicians should factor these in before concluding that an abnormal result reflects active disease. For practical frameworks on hormone level interpretation in clinic and similar lab contexts, the same principle applies: the biological variable cannot be separated from the measurement context.

Key variables to consider:

• Sample handling: Prolonged storage at room temperature before centrifugation causes in vitro complement consumption. Results from poorly handled samples are systematically falsely low.
• Haemolysis: Interferes with nephelometric assay methods. Visibly haemolysed samples should be rejected and recollected.
• Medications: Androgens (danazol, stanozolol) used in HAE prophylaxis can raise C4 levels as part of their therapeutic mechanism. This should not be misread as a disease response. Immunosuppressants used in SLE can also modulate complement levels indirectly.
• Pregnancy: C4 rises modestly as an acute-phase reactant in normal pregnancy. A result that looks borderline normal in a pregnant patient might represent a relative fall from their higher baseline.
• C4A/C4B null alleles: As discussed above, genetic copy number variation produces constitutively low C4 independent of disease activity.

Clinics that manage patients on long-term immunomodulatory therapies benefit from managing chronic inflammatory conditions with a clear audit trail of medications, doses, and lab results. Correlating medication changes with complement trends is only possible when both are recorded in the same system.

Structured patient record management software allows clinicians to view serial complement results alongside medication history, flagging discrepancies that might otherwise go unnoticed between appointments.

Conclusion

The c4 complement blood test is a precise tool when used in the right context. Low C4 in active lupus, undetectable C4 between HAE episodes, and the low C4/low C3 pattern in immune-complex glomerulonephritis each tell a distinct clinical story. But that story only emerges when results are tracked over time, alongside medications, symptoms, and other biomarkers.

Pabau’s lab management software gives clinics the infrastructure to track serial complement panels, link results to clinical notes, and surface patterns across patient visits. To see how it fits into a rheumatology or functional medicine workflow, book a demo.

Continue your research

Need a framework for communicating uncertain lab results to patients? Interpreting biomarkers without overpromising covers how to present complex lab values clearly without overstating diagnostic certainty.

Running a functional medicine or integrative practice? Integrative medicine practice management explores how Pabau supports complex multi-panel testing workflows and longitudinal patient tracking.

Want to improve how your team documents abnormal results? Safer clinical documentation provides a practical guide to writing clinical notes that hold up under audit and support continuity of care.

Frequently Asked Questions